ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: An improved therapy regimen employing selective tyrosine kinase inhibitors (TKI) directed at the abnormal BCR::ABL1 tyrosine kinase led to durable cytogenetic (CyR) and molecular response (MR) in the majority of patients with chronic myeloid leukemia (CML), thus achieving an almost normal life expectancy [1,2].